Table 2.
Clinicopathologic features of patients treated with gemcitabine
| Low dCK | High dCK | P | |
|---|---|---|---|
| Age (y) | 70.3 ± 8.1 | 59.8 ± 7.4 | <0.0006 |
| Gender (M/F) | 3/6 | 17/6 | <0.04 |
| Race (white/black) | 8/1 | 20/3 | NS |
| Tumor differentiation* | |||
| Well/moderate (n = 12) | 4 | 8 | NS |
| Poor (n = 10) | 2 | 8 | |
| Positive margins* | |||
| Yes (n = 3) | 1 | 2 | NS |
| No (n = 18) | 4 | 14 | |
| Clinical stage | |||
| I | 0 | 2 | NS |
| II | 3 | 1 | |
| III | 5 | 14 | |
| IV | 1 | 6 | |
| CA19-9 decrease ≥ 25% | |||
| Yes (n = 7) | 3 | 4 | NS |
| No (n = 15) | 2 | 13 | |
| Overall survival (mo) | 14.6 ± 7.3 | 21.7 ± 13.8 | <0.009 |
| Overall survival following gemcitabine initiation (mo) | 10.0 ± 5.3 | 12.0 ± 9.3 | <0.04 |
| Gemcitabine single agent | |||
| Yes (n = 11) | 3 | 8 | NS |
| No (n = 21) | 6 | 15 |
*
This information was only available for patients who underwent surgical resection.